2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1275

Dual-Energy CT for the Diagnosis of Gout: A Prospective Study in Patients with No Prior History of Gout

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1084

Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1330

Dyskeratotic Cells in Persistent Pruritic Skin Lesions Are Apoptotic and Associated with High Levels of Serum IL-18, and Possibly Predict the Outcomes in Adult-Onset Still’s Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1471

ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1276

Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1525

Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1226

Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1724

Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1740

Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1490

Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1400

Effects of Childhood-Onset SLE on Academic Achievements and Employment in Adult Life

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1036

Effects of Three Potential Anabolic Disease-Modifying Osteoarthritis Drugs – Sprifermin, Insulin-like Growth Factor 1 and Bone Morphogenetic Protein 7 – on Matrix Production and the Phenotype of Articular Chondrocytes

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1291

Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1769

Efficacy and Safety of Biomimic Rituximab in Granulomatosis with Polyangiitis – Experience from a Single Tertiary Care Centre in India

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 1546

Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].